Letrozole
Obesity and Cardiovascular Risk
University Of Nigeria Teaching HospitalSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Obesity and Cardiovascular Risk cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Metformin University Of Nigeria Teaching Hospital | Phase 3 | B |
Bge-102 BioAge Labs, Inc. | Phase 2 | CCC |
Same molecule, other indications
Letrozole is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →